UB Paderborn / Katalog / Suche / in CDI

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Annals of oncology, 2021-04, Vol.32 (4), p.488-499

2021

Volltextzugriff (PDF)

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Annals of oncology, 2016-11, Vol.27 (11), p.2046-2052

2016

Volltextzugriff (PDF)

Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials

Annals of oncology, 2018-10, Vol.29, p.viii608-viii609

2018

Volltextzugriff (PDF)

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

British journal of cancer, 2014-11, Vol.111 (11), p.2051-2057

2014

Volltextzugriff (PDF)

New approaches for the classification of early breast cancer, a heterogeneous disease entity

Memo - Magazine of European medical oncology, 2011-09, Vol.4 (3), p.135-139

Kahán, Z.

2011

Volltextzugriff (PDF)

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

European journal of cancer (1990), 2015-09, Vol.51, p.S263-S264

2015

Volltextzugriff (PDF)

Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer

Anticancer research, 2013-04, Vol.33 (4), p.1737-1741

2013

Volltextzugriff (PDF)

Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers

The journal of clinical endocrinology and metabolism, 1999-02, Vol.84 (2), p.582-589

1999

Volltextzugriff (PDF)

The relationship of multifocality and tumor burden with various tumor characteristics and survival in early breast cancer

Neoplasma, 2012, Vol.59 (5), p.566-573

2012

Volltextzugriff (PDF)

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

European journal of cancer (1990), 2012-11, Vol.48 (17), p.3140-3149

2012

Volltextzugriff (PDF)

Synthesis and Biological Evaluation of Cytotoxic Analogs of Somatostatin Containing Doxorubicin or Its Intensely Potent Derivative, 2-pyrrolinodoxorubicin

Proceedings of the National Academy of Sciences - PNAS, 1998-02, Vol.95 (4), p.1794-1799

1998

Volltextzugriff (PDF)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

The lancet oncology, 2013-02, Vol.14 (2), p.125-133

2013

Volltextzugriff (PDF)

Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin

Annals of oncology, 2017-09, Vol.28, p.v555-v555

2017

Volltextzugriff (PDF)

1700PSafe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice

Breast cancer research and treatment, 2000-03, Vol.60 (1), p.71-79

2000

Volltextzugriff (PDF)

229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

Annals of oncology, 2021-09, Vol.32, p.S457-S458

2021

Volltextzugriff (PDF)

143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study

Annals of oncology, 2020-05, Vol.31, p.S66-S67

2020

Volltextzugriff (PDF)

P689Examination of radiation-induced heart damage using in vitro and in vivo animal models

Cardiovascular research, 2014-07, Vol.103 (suppl 1), p.S126-S126

2014

Volltextzugriff (PDF)

Insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3 and breast cancer (BC) risk: A synthetic case-control study

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.9610-9610

Kahan, Z.

2004

Volltextzugriff (PDF)

Insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3 and breast cancer (BC) risk: A synthetic case-control study

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.9610-9610

Kahan, Z.

2004

Volltextzugriff (PDF)

Bone Homeostasis and Breast Cancer: Implications for Complex Therapy and the Maintenance of Bone Integrity

Pathology oncology research, 2013, Vol.19 (1), p.1-10

2013

Volltextzugriff (PDF)

Ocular abnormality as the first sign of metastatic breast cancer: the presentation of two cases

Memo - Magazine of European medical oncology, 2008-09, Vol.1 (3), p.153-155

2008

Volltextzugriff (PDF)

Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix

International journal of oncology, 2000-08, Vol.17 (2), p.367

2000

Volltextzugriff (PDF)

Abstract OT2-01-06: Phase III study of p albociclib (PD-0332991) in combination with e ndocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with r esistance to a romatase inhibitors. “The PEARL study” (GEICAM/2013-02)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-06-OT2-01-06

2017

Volltextzugriff (PDF)

Inhibition of growth of MDA‐MB‐468 estrogen‐independent human breast carcinoma by bombesin/gastrin‐releasing peptide antagonists RC‐3095 and RC‐3940‐II

Cancer, 2000-03, Vol.88 (6), p.1384-1392

2000

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

New approaches for the classification of early breast cancer, a heterogeneous disease entity

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer

Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers

The relationship of multifocality and tumor burden with various tumor characteristics and survival in early breast cancer

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

Synthesis and Biological Evaluation of Cytotoxic Analogs of Somatostatin Containing Doxorubicin or Its Intensely Potent Derivative, 2-pyrrolinodoxorubicin

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin

1700PSafe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice

229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study

P689Examination of radiation-induced heart damage using in vitro and in vivo animal models

Insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3 and breast cancer (BC) risk: A synthetic case-control study

Insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3 and breast cancer (BC) risk: A synthetic case-control study

Bone Homeostasis and Breast Cancer: Implications for Complex Therapy and the Maintenance of Bone Integrity

Ocular abnormality as the first sign of metastatic breast cancer: the presentation of two cases

Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix

Inhibition of growth of MDA‐MB‐468 estrogen‐independent human breast carcinoma by bombesin/gastrin‐releasing peptide antagonists RC‐3095 and RC‐3940‐II

Suchergebnisse filtern